15 results about "Tumour immunotherapy" patented technology

The present invention discloses biphenyloxadiazole ether derivatives as immune checkpoint inhibitors capable of blocking the PD-1 / PD-L1 signaling pathway, as well as their preparation methods and uses. These compounds, as shown in Formula I below, can modulate the PD-1 / PD-L1 signaling pathway to treat a variety of related tumor diseases through tumor immunotherapy, demonstrating potential drug development. The biphenyloxadiazole ether derivatives of the present invention, or their pharmaceutically acceptable salts, racemates, optical isomers, or solvates, are also disclosed. #imgabs0#

The application relates to the technical field of tumor drugs, in particular to application of METTL5 as a tumor immunotherapy targeting site. The base sequence of the METTL5 is shown in SEQ ID No. 1; wherein the METTL5 is a brand-new RNAm6A methyltransferase, is closely related to ribosome translation function, and can regulate the translation of a tumor immune key regulator IL-27; therefore, the METTL5 is used as the tumor immunotherapy targeting site, the expression of the METTL5 related genes or coding proteins is inhibited through targeting, the body anti-tumor immunity can be effectively stimulated, the METTL5 becomes the targeting site capable of enhancing the response rate of tumor immunotherapy, and the METTL5 used as the tumor treatment target point has a wide application prospect in the anti-tumor immunotherapy.

Provided herein are methods, compositions, and kits for treating tumors by combining patient-derived immune effector cells with cytokine and therapeutic agents. In one aspect, apheresis material is processed to isolate at least two products selected from T cell, NK cell, and dendritic cell populations, which are formulated and administered to the patient. In another aspect, invariant natural killer T (iNKT) cells are expanded ex vivo using an IL-15:IL-15Rα complex and α-galactosylceramide delivered on a bacterial minicell nanoparticle, enabling scalable production of functional cells. Additional embodiments include tumor microenvironment preconditioning regimens and use of IL-15 superagonists to convert "cold" tumors into "hot" tumors.

The application belongs to the technical field of drug delivery carrier, and particularly relates to a dual-metal nanodot-oncolytic virus intravenous delivery system and a preparation method and application thereof in tumor immunotherapy. The oncolytic adenovirus is used as raw material, and the dual-metal nanodot-adenovirus chimera is constructed by using the covalent force of 4-maleimide butyric acid-N-succinimidyl ester. The preparation performance, cytotoxicity, action mechanism, in-vivo anti-tumor effect, anti-tumor immunity, anti-tumor recurrence and anti-tumor metastasis effect of the chimera are evaluated. The preparation process is simple, the prepared dual-metal nanodot-adenovirus chimera has small and uniform particle size, is conducive to enrichment in tumor tissues through the enhanced permeability and retention (EPR) effect, has high drug loading capacity, good safety and can generate high-intensity MRI signals at the tumor site. The designed dual-metal nanodot-adenovirus chimera realizes the integration of tumor diagnosis and treatment.

The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in the treatment of cancer.

The present application relates to chimeric receptors, in particular chimeric receptors comprising homodimeric polypeptides. Uses of these receptors in tumor immunotherapy adoptive cell therapy) are also disclosed. The application further relates to methods of genetically modifying a therapeutic immune cell, eliciting an enhanced immune response against a target antigen. The application further relates to therapeutic cells expressing the chimeric receptors and methods of treating patients using the modified therapeutic cells.

The present application relates to the use of hydroxyphenyl propionate compounds of formula (I), (II), (III), (IV) or (V) or pharmaceutically acceptable salts, solvates and / or ester prodrugs thereof for increasing anti-tumor immunity, to compositions comprising them, and to their use, for example, in cancer immunotherapy. More specifically, the present application relates to compounds useful in the treatment of diseases, disorders or conditions that can be treated by increasing the anti-tumor immunity of cells, such as cancer.

The invention belongs to the technical field of biotechnology and cell culture, and particularly relates to an additive for improving killing activity of NK cells, a culture medium and application of the additive and the culture medium. The additive for improving the killing activity of the NK cells comprises an inducer and an amplification agent, the inducer is prepared from auricularia auricula polysaccharide, IL-2, IL-15 and IL-18; the amplification agent is prepared from timosaponin, isoalantolactone, tannic acid and IL-2 (Interleukin-2). By adding the black fungus polysaccharide auxiliary cytokines, the NK cells can be effectively activated in the induction period, and the expansion efficiency of the NK cells is promoted to be improved; according to the NK cell proliferation culture medium, the NK cell proliferation culture medium is added with the isoalantolactone, the tannic acid and the cell factors for synergistic cooperation in the proliferation period, the proportion of CD3-CD56 + cells can be effectively increased on the basis of achieving NK cell proliferation culture, the immunocompetence of the NK cells and the killing effect of tumor cells are enhanced, and application of the NK cells in tumor immunotherapy is promoted.

The invention relates to the technical field of tumor immunotherapy, and particularly discloses a screening method of a cancer cell mitochondrial DNA (deoxyribonucleic acid) coding new antigen, mitochondrial DNA with higher purity is obtained by means of microdissection, linear DNA splitting and the like, and nuclear metastasis mitochondrial fragment interference in mitochondrial sequencing is overcome. On the basis, mitochondrial amplicon sequencing is used for identifying the base sequence change caused by mutation from the DNA level, multiple types of tumor vaccines including polypeptide vaccines, RNA vaccines and dendritic vaccines can be prepared according to requirements, and even the tumor vaccines can be used for TCR-T therapy. According to the screening method of the mitochondrial DNA coding new antigen and the application of the mitochondrial DNA coding new antigen in preparation of the vaccine, the feasibility of the mitochondrial coding new antigen and the effectiveness of the mitochondrial coding new antigen as a tumor vaccine target are accurately and comprehensively confirmed, and a transcription translation process and a screening mechanism of DNA-RNA-polypeptide are systematically constructed; and more diversified, personalized, safe and effective treatment strategies can be selected and designed for the patient.

The present disclosure provides compositions and methods for inhibiting T cell senescence and improving T cell immunotherapies. In particular, inhibitors of group IV A phospholipase A2 are disclosed as useful in modulating the lipid metabolism of cells, in particular effector T cells, such that T reg- and tumor cell-induced cell senescence is abrogated. These methods may be employed with particular utility in adoptive T cell therapies and / or enhanced T cell effector functions in vivo, including those performed in combination with checkpoint blockade therapies.

Provided are a polypeptide targeting a KRAS mutant protein and a use thereof, a drug, and a method. The polypeptide can specifically bind to a KRAS G12 mutant protein binding domain, can exhibit high affinity to a KRAS G12X mutant protein (X=D, V, R, or C), with a picomolar-level equilibrium dissociation constant KD, and can specifically regulate and control a secondary structure of the KRAS G12X mutant protein (X=D, V, R, or C). The polypeptide conforming to specific amino acid composition and sequence characteristics and including SEQ ID NOs. 1-9 has the ability to induce death of KRAS G12X mutant (X=D, V, R, or C) tumor cells and, on this basis, enhances the therapeutic effect of existing chemotherapy and tumor immunotherapy. The polypeptide can be used as a therapeutic or auxiliary therapeutic drug for diseases, such as colon cancer, lung cancer, pancreatic cancer, breast cancer, osteogenic sarcoma and / or ovarian cancer, and has clinical application potential.

The present disclosure provides a chimeric antigen receptor (CAR) immunotherapy for treating a hematologic cancer comprising (a) genetically modifying a population of immune effector cells comprising T cell receptors (TCRs) to stably express at least one CAR, wherein the ectodomain of the CAR specifically binds a cancer antigen; (b) expanding the population of CAR-containing immune effector cells in the presence of one or more cytokines in vitro to achieve a therapeutic dose, wherein the population of CAR-containing immune effector cells exhibits a nonexhausted memory T cell phenotype; and (c) infusing eligible subjects with the CAR-containing immune effector memory T cell phenotype population of cells as needed until the hematologic cancer in the body is destroyed. The intracellular signal transduction domain of the CAR includes 4-1BB, a CD3zeta T cell activation chain and a genetically engineered 'TLE3, which can be ectopically expressed.

The present invention provides chimeric cytokine receptors, particularly chimeric cytokine receptors that can be activated in tumor microenvironment, and their uses in tumor immunotherapy (e.g., adoptive cell therapy). The present invention further provides methods of genetically modifying therapeutic cells resulting in an enhanced immune response against a target antigen. The application further provides therapeutic cells that express said chimeric cytokine receptors and methods for treating patients using the modified therapeutic cells.

The application relates to chimeric cytokine receptors, particularly chimeric cytokine receptors comprising one or more leucine zipper motifs, and their uses in tumor immunotherapy (e.g., adoptive cell therapy). The application further relates to methods of genetically modifying therapeutic immune cells resulting in an enhanced immune response against a target antigen. The application further relates to therapeutic cells that express said chimeric cytokine receptors and methods for treating patients using the modified therapeutic cells.

This invention belongs to the field of biomedical technology and relates to protein polyphenol nanocapsules, their preparation method, and their application in the preparation of nanovaccines. Eight-arm polyethylene glycol-hydroxyl groups, IMDQ, 2-MIM, and zinc salt are used in water as a solvent to prepare IMDQ-loaded ZIF-8 nanoparticles. The IMDQ-loaded ZIF-8 nanoparticles are dispersed in water, and OVA is added for mixing and reaction, allowing the IMDQ-loaded ZIF-8 nanoparticles to adsorb OVA. The OVA-adsorbed IMDQ-loaded ZIF-8 nanoparticles are then dispersed in water, and tannic acid is added for reaction, causing the tannic acid to etch ZIF-8 to form a hollow structure. This hollow structure serves as a framework for the interaction between tannic acid and OVA to form protein polyphenol nanocapsules. The protein polyphenol nanocapsules prepared by this invention exhibit good biocompatibility and immunogenicity and can be used as nanovaccines for tumor immunotherapy.